OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Optimising anal cancer screening through risk stratification	449
How do we prevent anal cancer in people living with HIV?	164
The Australian AIDS crisis through the eyes of volunteers	149
Evidence supports use of on-demand PrEP for HIV prevention	142
Lung cancer in people living with HIV	129
Transplant donation without discrimination	124
Argentina updates HIV laws	123
Steps toward quick and equitable roll-out of lenacapavir	120
How much could long-acting PrEP cost in South Africa?	120
Controversial chronicler of LGBTQ rights	113
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV	110
Correction to Lancet HIV 2022; 9: e791–800	102
Risk estimation in HIV reveals our usual blind spots	99
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	81
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	77
A moment of reckoning	71
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	70
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	69
Lenacapavir: an attractive option, but proceed with caution	67
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial	63
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	61
All roads lead to Westminster: the infected blood scandal	61
Are we ready for long-acting HIV treatment for adolescents?	61
Redefining care: injectable HIV treatment for adolescents	60
Making America unhealthy again	56

Equitable access to long-acting PrEP on the way?	56
Recent gay Black history in the UK	55
Reducing HIV transmission in British Columbia, Canada	55
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa:	53
Suicide prevention research is crucial to achieving health equity for people with HIV	49
Unheard testimony	49
Game-changing study of second-line HIV treatment	49
Gains and gaps: addressing HIV in diverse sex worker groups	49
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	48
Standardisation of monitoring routines for new long-acting antiretrovirals in development	48
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	46
Sex as a biological variable in HIV-1 and schistosome co-infection	46
Dolutegravir in neonates: finally we are getting there!	46
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	45
Preventing tuberculosis in advanced HIV disease	45
WHO recommends lenacapavir for HIV prevention	43
The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys	43
Integration of sexual health and HIV services	43